Tribute to Retina UK founder Lynda Cantor MBE
Tribute to Retina UK founder Lynda Cantor MBE
Search
Search results
Retina UK set to feature in BBC Lifeline Appeal
Catch up on our BBC Lifeline Appeal from November 2025.
Free ferry travel for companions available in Scotland
People living with sight loss in Scotland are able to benefit from free ferry travel for their companion when travelling with Caledonian MacBrayne (CalMac) Ferries with the NEC+1 card. The ferries operate across Scotland’s islands.
SparingVision completes dosing in PRODYGY trial of SPVNO6 for retinitis pigmentosa.
SparingVision have announced this week that they have dosed all participants in their phase 1/2 PRODYGY clinical trial for SPVN06, a gene agnostic therapy aimed at slowing disease progression in Retinitis Pigmentosa (RP).
PDE6A gene therapy trial report: the importance of scientific learnings in an unsuccessful trial
Researchers from the University Hospital Tübingen in Germany recently announced that there were no signs of visual gains in an early-phase clinical trial of a PDE6A gene therapy for Retinitis Pigmentosa (RP).
New nanoparticle gene therapy research provides hope for treating inherited sight loss
Researchers from Ghent University have published a study that has the potential to transform inherited retinal disease (IRD) treatment development.
Research opportunity for people with confirmed Stargardt disease
Please find below a research opportunity for people with confirmed stargardt disease.
Notice of the forthcoming Retina UK AGM – July 2026
Formal notice of the forthcoming Annual General Meeting in July 2026.
Clinical Trial Opportunity for Adults with Stargardt Disease
The clinical trial team at The Retina Clinic London have asked us to share an opportunity to participate in a Phase 1 clinical trial for AAVB 039 for Stargardt Disease.
From Lab to Clinical Trial: First Healthy Volunteer Dosed with OCT-980
Octant, a clinical stage drug discovery company, has recently announced the dosing of the first healthy volunteer in their Phase 1a clinical trial of OCT-980 for Rhodopsin-associated autosomal dominant Retinitis Pigmentosa (RHO-adRP).